Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16946101 | 0.79 | EPHX1 (0.47) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL17147519 | 0.79 | EPHX1 (0.33) | EPHX1CA2CA1 | |
| SCHEMBL11173595 | 0.79 | EPHX1 (0.42) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL12789664 | 0.77 | EPHX1 (0.60) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL1618552 | 0.75 | EPHX1 (0.39) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL6305655 | 0.75 | EPHX1 (0.44) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL1024523 | 0.74 | CA1 (0.33) | CA2CA1CA7CA13 | |
| SCHEMBL2835677 | 0.72 | POLB (0.34) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL906373 | 0.72 | EPHX1 (0.45) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL3371130 | 0.72 | CA1 (0.32) | EPHX1CA2CA1CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240253023-A1 | PERFLUORINATED AMIDE SALTS AND THEIR USES AS IONIC CONDUCTING MATERIALS | MICHOT CHRISTOPHE (FR) | 2024-08-01 | — | — | US | disclosed |
| US-11754926-B2 | Method of forming resist pattern, resist composition and method of producing the same | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-09-12 | — | — | US | disclosed |
| US-11667731-B2 | Stabilized UV active organopalladium compounds as vinyl addition catalysts | PROMERUS, LLC (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230127914-A1 | RESIST PATTERN FORMATION METHOD | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-23 | — | — | US | disclosed |
| US-9929343-B2 | Organic semiconductor doping process | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| EP-2325695-B1 | RADIATION-SENSITIVE RESIN COMPOSITION | JSR CORP (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9818944-B2 | Organic semiconductor doping process | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-11-14 | — | — | US | disclosed |
| US-20160240781-A1 | ORGANIC SEMICONDUCTOR DOPING PROCESS | OXFORD PHOTOVOLTAICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-20160126020-A1 | ORGANIC SEMICONDUCTOR DOPING PROCESS | OXFORD PHOTOVOLTAICS LIMITED (GB) | 2016-05-05 | — | — | US | disclosed |
| US-20120082936-A1 | RADIATION-SENSITIVE RESIN COMPOSITION | JSR CORPORATION (JP) | 2012-04-05 | — | — | US | disclosed |
| US-20120082936-A1 | RADIATION-SENSITIVE RESIN COMPOSITION | JSR CORPORATION (JP) | 2012-04-05 | — | — | US | disclosed |
| US-20110223537-A1 | RADIATION-SENSITIVE RESIN COMPOSITION AND POLYMER | JSR CORPORATION (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110223537-A1 | RADIATION-SENSITIVE RESIN COMPOSITION AND POLYMER | JSR CORPORATION (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20100099694-A1 | 2-ANILINO-4-HETEROARYL PYRIMIDINE DERIVATIVES, AND PREPARATION THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-22 | — | — | US | disclosed |
| EP-2108016-A1 | 2-ANILINO-4-HETEROARYL PYRIMIDINE DERIVATIVES, AND PREPARATION THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR IKK INHIBITORS | Sanofi-Aventis (FR) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008099075-A1 | 2-ANILINO-4-HETEROARYL PYRIMIDINE DERIVATIVES, AND PREPARATION THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
| EP-0089487-B1 | NOVEL N,N'-BIS(TRIFLUOROMETHYLSULFONYL)OXAMIDES AND CHEMILUMINESCENT COMPOSITIONS CONTAINING THE SAME | AMERICAN CYANAMID COMPANY (US) | 1987-06-16 | — | — | EP | disclosed |
| US-4407743-A | REACTION WITH PEROXIDE IN PRESENCE OF FLUORESCER | AMERICAN CYANAMID COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0089487-A2 | Novel N,N'-bis(trifluoromethylsulfonyl)oxamides and chemiluminescent compositions containing the same | AMERICAN CYANAMID COMPANY (US) | 1983-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099694-A1 | 2-ANILINO-4-HETEROARYL PYRIMIDINE DERIVATIVES, AND PREPARATION THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR IKK INHIBITORS | CHUK, IKBKB, IKBKE | EPHX1 3024/4885CA2 4252/4885CA1 4822/4885 |
| US-20240253023-A1 | PERFLUORINATED AMIDE SALTS AND THEIR USES AS IONIC CONDUCTING MATERIALS | AFF4, AFF2, AFF1 | EPHX1 1533/4885CA2 303/4885CA1 627/4885 |
| US-10266503-B1 | Sulfoxide ligand metal catalyzed oxidation of olefins | YAP1, ICOSLG, SPIN3 | EPHX1 2305/4885CA2 3802/4885CA1 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.